This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Undervalued Stocks From Cheapest Sector

BOSTON ( TheStreet) -- Health care is the stock market's cheapest sector, based on earnings projections. The average S&P 500 health-care stock sells for a forward price-to-earnings ratio of less than 12. Here's a look at seven undervalued health-care stocks selling at even bigger discounts. A rotation from risk into quality will benefit these investments in 2011 and beyond. Researcher JPMorgan recommends overweighting each of these equities.

Below, the stocks are ordered by forward P/E.

7. Amgen (AMGN - Get Report) is a seasoned biotechnology company, with a market value of $51 billion.

Since 2008, it has grown net income and earnings per share 13% and 20%, annually, on average. Amgen's adjusted fourth-quarter earnings inched up 1% to $1.17, beating analysts' consensus estimate by 5.9%. Its sales rose 1%, as well, past $3.8 billion, matching the consensus forecast. Amgen is exceptionally cheap, trading at a trailing P/E of 11, a forward P/E of 9.7 and a book value multiple of 2.1, 40%, 54% and 67% discounts to biotechnology industry averages.

JPMorgan, ranking the stock "overweight", was impressed by management's 2011 guidance and expects it to be in a beat-and-raise environment in 2011 as there are notably low expectations for the company's legacy products and solid growth prospects for the company's denosumab antibody franchise. Amgen recently announced plans to purchase OncoVex, which has a drug for head and neck melanoma in stage three of FDA approval. JPMorgan's $65 target suggests 19% upside. Currently, 70% of analysts rate Amgen "buy."

Bullish Scenario: Piper Jaffray rates Amgen "overweight", expecting an advance to $73.

Bearish Scenario: Goldman Sachs ranks Amgen "sell", forecasting a fall of 8% to $50.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
AMGN $163.84 0.00%
ABT $49.34 0.00%
CI $132.95 0.00%
GILD $111.22 0.00%
JPM $66.65 0.00%

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs